Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10505)	6/18/1999 1:02:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

To be fair XOMA is/was the only biotech or drug company I know that gave regular updates on accruals in their clinical trials. But I bought more of XOMA exactly because they do or did such a good job in providing shareholders with information. Sure, they slipped up at times and even in important ways. But overall they are so much better. But if they begin to copy the non informative style of other companies I will be disappointed. BTW just got message, that I had not checked before. Accruals for Trauma are 924.